No current GLP-1 label lists menopause as an approved use, so prescribing one for it would be off-label. Look-back study (Semaglutide): In postmenopausal women on semaglutide, those also on hormone therapy had lost 16% of their weight at 12 months, and those not on it 12%. A small study that shows a link, not a cause. It measured weight, not menopause symptoms. ClinicalTrials.gov lists 14 trials of these medicines on it: 0 with posted results and 3 recruiting now.
Read from the registry and PubMed every day. The newest update here is Nov 4, 2026.
Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.
Semaglutide · 106 people · Mixed · Observational study
In postmenopausal women on semaglutide, those also on hormone therapy had lost 16% of their weight at 12 months, and those not on it 12%. A small study that shows a link, not a cause. It measured weight, not menopause symptoms.
A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.
| Medicine | Trials | Posted results | Recruiting |
|---|---|---|---|
| Semaglutide | 7 | 0 | 1 |
| Tirzepatide | 2 | 0 | 2 |
| Exenatide | 1 | 0 | 0 |
| Liraglutide | 1 | 0 | 0 |
| MariTide | 1 | 0 | 0 |
| Retatrutide | 1 | 0 | 0 |
| Survodutide | 1 | 0 | 0 |
The registry page names each site and who can enroll. Ask your clinician before joining one.
| Trial | Medicine | Phase | Expected to finish |
|---|---|---|---|
| Focusing on the Menopausal Transition to Improve Mid-Life Women's Health | Semaglutide | Phase 2/3 | Oct 1, 2030 |
| The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity | Tirzepatide | Phase 4 | Sep 18, 2027 |
| Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors | Tirzepatide | Phase 4 | Feb 25, 2028 |
Written from each source's own record as it changes. Every change on GLPcompare
Look-back study (Semaglutide, 106 people): In postmenopausal women on semaglutide, those also on hormone therapy had lost 16% of their weight at 12 months, and those not on it 12%. A small study that shows a link, not a cause. It measured weight, not menopause symptoms.
Not in any current label we read. A prescriber can still use a medicine off-label, but insurance often limits coverage to approved uses, so ask your plan.
Semaglutide, with 7 registered trials on it, then Tirzepatide with 2. More trials do not mean better results: read what each posted.
3 trials are recruiting on ClinicalTrials.gov now, listed below with their registry pages, which name each site and who can enroll.